HEPA - Hepion Pharma reports anti-cancer activity of CRV431 in a liver cancer study in mice

Hepion Pharmaceuticals (NASDAQ:HEPA) announces the results of a nonclinical research study showing that CRV431 significantly decreased the growth of liver tumors in a mouse model of liver cancer. In this study, mouse hepatocellular cancer (HCC) cells were surgically implanted into livers of recipient mice. In the absence of drug treatment, large tumors developed over a period of 28 days. Treatment with CRV431 or an anti-PD1 antibody each decreased tumor size by 76%, while the CRV431/anti-PDI antibody combination treatment decreased tumor size by 83%, compared to the vehicle treatment (no drug). Also, CRV431 beneficially doubled the number of tumor-infiltrating CD4 and CD8 lymphocytes. This same finding was observed with anti-PD1 treatment, suggesting that both treatments stimulated immunity against the tumors. Furthermore, CRV431 decreased the number of neutrophils in the tumors by 55%, which was not observed with anti-PD1 antibody treatment. HEPA shares up 1.4% premarket at $1.49.

For further details see:

Hepion Pharma reports anti-cancer activity of CRV431 in a liver cancer study in mice